<p>Although there is no known cure for <a href="multiple_sclerosis" title="wikilink">multiple sclerosis</a> (MS), several <strong>therapies for multiple sclerosis</strong> have proven helpful. Multiple sclerosis is a <a href="chronic_(medicine)" title="wikilink">chronic</a> <a href="Inflammation" title="wikilink">inflammatory</a> <a href="demyelinating_disease" title="wikilink">demyelinating disease</a> that affects the <a href="Central_Nervous_System" title="wikilink">central nervous system</a> (CNS).</p>
<p>The most common initial course of the disease is the relapsing-remitting subtype, which is characterized by unpredictable attacks (<a href="relapse" title="wikilink">relapses</a>) followed by periods of relative remission with no new signs of disease activity. After some years, many of the people who have this subtype begin to experience neurologic decline without acute relapses as the secondary progressive subtype. Other, less common, courses of the disease are the primary progressive (decline from the beginning without attacks) and the progressive-relapsing (steady neurologic decline and superimposed attacks). Different therapies are used for patients experiencing acute attacks, for patients who have the relapsing-remitting subtype, for patients who have the progressive subtypes, for patients without a <a href="diagnosis" class="uri" title="wikilink">diagnosis</a> of MS who have a <a href="Demyelinating_disease" title="wikilink">demyelinating</a> event, and for managing the various consequences of MS.</p>
<p>The primary aims of therapy are returning function after an attack, preventing new attacks, and preventing disability. As with any medical treatment, medications used in the management of MS have several <a href="adverse_effect_(medicine)" title="wikilink">adverse effects</a>, and many possible therapies are still under investigation. At the same time different <a href="Alternative_medicine" title="wikilink">alternative treatments</a> are pursued by many patients, despite the paucity of supporting, comparable, replicated scientific study.</p>
<p>This article focuses on therapies for standard MS; <a href="idiopathic_inflammatory_demyelinating_diseases" title="wikilink">borderline forms of MS</a> have particular treatments that are excluded.</p>
<h2 id="management-of-acute-attacks">Management of acute attacks</h2>
<figure>
<img src="Methylprednisolone.svg" title="Chemical structure of methylprednisolone. Corticosteroids are used during acute multiple sclerosis relapses." alt="Chemical structure of methylprednisolone. Corticosteroids are used during acute multiple sclerosis relapses." /><figcaption>Chemical structure of methylprednisolone. Corticosteroids are used during acute multiple sclerosis relapses.</figcaption>
</figure>
<p>During symptomatic attacks, patients may be hospitalized. As of 2007, administration of high doses of <a href="intravenous_therapy" title="wikilink">intravenous</a> <a href="corticosteroid" title="wikilink">corticosteroids</a>, such as <a href="methylprednisolone" class="uri" title="wikilink">methylprednisolone</a>,<a href="#fn1" class="footnote-ref" id="fnref1"><sup>1</sup></a><a href="#fn2" class="footnote-ref" id="fnref2"><sup>2</sup></a> is the routine therapy for acute relapses. This is administered over a period of three to five days, and has a well-established <a href="efficacy" class="uri" title="wikilink">efficacy</a> in promoting a better recovery from <a href="disability" class="uri" title="wikilink">disability</a>.<a href="#fn3" class="footnote-ref" id="fnref3"><sup>3</sup></a><a href="#fn4" class="footnote-ref" id="fnref4"><sup>4</sup></a></p>
<p>The aim of this kind of treatment is to end the attack sooner and leave fewer lasting deficits in the patient. Although generally effective in the short term for relieving <a href="symptom" title="wikilink">symptoms</a>, corticosteroid treatments do not appear to have a significant impact on long-term recovery: steroids produce a rapid improvement from disability, but this improvement only lasts up to thirty days following a clinical attack and is not evident thirty-six months after the attack. This treatment does not reduce the number of patients who subsequently develop a clinical <a href="relapse" class="uri" title="wikilink">relapse</a>.<a href="#fn5" class="footnote-ref" id="fnref5"><sup>5</sup></a></p>
<p>Recent studies suggest that steroids administered orally are just as effective at treating MS symptoms as intravenous treatment. However, short term treatment with high-dose intravenous corticosteroids does not seem to be attended by <a href="adverse_drug_reaction" title="wikilink">adverse effects</a>; on the contrary, <a href="gastrointestinal" class="uri" title="wikilink">gastrointestinal</a> symptoms and psychiatric disorders are more common with oral corticosteroids.<a href="#fn6" class="footnote-ref" id="fnref6"><sup>6</sup></a></p>
<h2 id="disease-modifying-treatments">Disease-modifying treatments</h2>
<h3 id="clinically-isolated-syndrome">Clinically isolated syndrome</h3>
<p>The earliest clinical presentation of relapsing-remitting MS (RRMS) is the clinically isolated syndrome (CIS). During a CIS, there is a subacute attack suggestive of <a href="demyelination" class="uri" title="wikilink">demyelination</a> but the patient does not fulfill the <a href="McDonald_criteria" title="wikilink">criteria</a> for diagnosis of multiple sclerosis.<a href="#fn7" class="footnote-ref" id="fnref7"><sup>7</sup></a> Several studies have shown that treatment with <a href="interferon" title="wikilink">interferons</a> during an initial attack can decrease the chance that a patient will develop MS. These results support the use of interferon after a first clinical demyelinating event and indicate that there may be modest beneficial effects of immediate treatment compared with delayed initiation of treatment.<a href="#fn8" class="footnote-ref" id="fnref8"><sup>8</sup></a><a href="#fn9" class="footnote-ref" id="fnref9"><sup>9</sup></a><a href="#fn10" class="footnote-ref" id="fnref10"><sup>10</sup></a></p>
<h3 id="relapsing-remitting-ms">Relapsing-remitting MS</h3>
<figure>
<img src="Injection_23.JPG" title="Disease-modifying treatments are expensive and require frequent injections." alt="Disease-modifying treatments are expensive and require frequent injections." /><figcaption>Disease-modifying treatments are expensive and require frequent injections.</figcaption>
</figure>
<p>As of 2007, six disease-modifying treatments have been approved by regulatory agencies of different countries, including the U.S. <a href="Food_and_Drug_Administration" title="wikilink">Food and Drug Administration</a> (FDA), the <a href="European_Medicines_Agency" title="wikilink">European Medicines Agency</a> (EMEA) and the Japanese <a href="Ministry_of_Health,_Labour_and_Welfare_(Japan)" title="wikilink">PMDA</a>. Three are <a href="interferon" title="wikilink">interferons</a>: two formulations of <a href="interferon_beta-1a" title="wikilink">interferon beta-1a</a> (trade names <em>Avonex</em> and <em>Rebif</em>; the first given weekly, the latter three times a week),<a href="#fn11" class="footnote-ref" id="fnref11"><sup>11</sup></a><a href="#fn12" class="footnote-ref" id="fnref12"><sup>12</sup></a> and one of <a href="interferon_beta-1b" title="wikilink">interferon beta-1b</a> (U.S. trade name <em>Betaseron</em>, in Europe and Japan <em>Betaferon</em>).<a href="#fn13" class="footnote-ref" id="fnref13"><sup>13</sup></a> Interferons are <a href="medication" title="wikilink">medications</a> derived from human <a href="cytokine" title="wikilink">cytokines</a> which help to regulate the <a href="immune_system" title="wikilink">immune system</a>. A fourth medication is <a href="glatiramer_acetate" title="wikilink">glatiramer acetate</a> (<em>Copaxone</em>),<a href="#fn14" class="footnote-ref" id="fnref14"><sup>14</sup></a> a mixture of <a href="peptide" title="wikilink">polypeptides</a> which may protect important <a href="myelin" class="uri" title="wikilink">myelin</a> <a href="protein" title="wikilink">proteins</a> by substituting itself as the target of <a href="Autoimmunity" title="wikilink">immune system attack</a>.<a href="#fn15" class="footnote-ref" id="fnref15"><sup>15</sup></a> The fifth medication, <a href="mitoxantrone" class="uri" title="wikilink">mitoxantrone</a>, is an <a href="immunosuppressant" class="uri" title="wikilink">immunosuppressant</a> also used in <a href="chemotherapy" title="wikilink">cancer chemotherapy</a>. Finally, the sixth is <a href="natalizumab" class="uri" title="wikilink">natalizumab</a> (marketed as <em>Tysabri</em>), a <a href="Monoclonal_antibody_therapy" title="wikilink">monoclonal antibody</a>.<a href="#fn16" class="footnote-ref" id="fnref16"><sup>16</sup></a></p>
<p>All six medications are modestly effective at decreasing the number of attacks and slowing progression to disability, although they differ in their efficacy rate. Comparisons between immunomodulators (all but mitoxantrone) show that the most effective is natalizumab, but studies of its long-term effects are still lacking.<a href="#fn17" class="footnote-ref" id="fnref17"><sup>17</sup></a> Mitoxantrone is probably the most effective of them all;<a href="#fn18" class="footnote-ref" id="fnref18"><sup>18</sup></a> however, its use is limited by severe <a href="cardiotoxicity" class="uri" title="wikilink">cardiotoxicity</a>.<a href="#fn19" class="footnote-ref" id="fnref19"><sup>19</sup></a> This is the reason why it is mainly used to treat MS patients who have worsening relapsing-remitting or secondary progressive multiple sclerosis despite prior therapy with interferons or glatiramer acetate.</p>
<p>Medications also differ in ease of use, price and side effects.<a href="#fn20" class="footnote-ref" id="fnref20"><sup>20</sup></a> All of these therapies are expensive and require frequent <a href="Injection_(medicine)" title="wikilink">injections</a>, with <em>Tysabri</em> given as <a href="intravenous" class="uri" title="wikilink">intravenous</a> infusions every four weeks,<a href="#fn21" class="footnote-ref" id="fnref21"><sup>21</sup></a> <em>Avonex</em> requiring weekly injections,<a href="#fn22" class="footnote-ref" id="fnref22"><sup>22</sup></a> <em>Rebif</em> three times a week,<a href="#fn23" class="footnote-ref" id="fnref23"><sup>23</sup></a> and <em>Copaxone</em> and <em>Betaseron</em> daily injections.<a href="#fn24" class="footnote-ref" id="fnref24"><sup>24</sup></a><a href="#fn25" class="footnote-ref" id="fnref25"><sup>25</sup></a> Mitoxantrone is intravenously administered every three months as a slow <a href="Intravenous_therapy" title="wikilink">infusion</a> over at least thirty minutes.</p>
<p>Even with appropriate use of medication, most patients with relapsing-remitting MS still suffer from some attacks and subsequent disability.</p>
<h3 id="progressive-ms">Progressive MS</h3>
<figure>
<img src="Mitoxantrone_skeletal.svg" title="Chemical structure of mitoxantrone. In 2007 it was the only approved treatment for secondary progressive multiple sclerosis." alt="Chemical structure of mitoxantrone. In 2007 it was the only approved treatment for secondary progressive multiple sclerosis." /><figcaption>Chemical structure of mitoxantrone. In 2007 it was the only approved treatment for secondary progressive multiple sclerosis.</figcaption>
</figure>
<p>Treatment of progressive MS is more difficult than relapsing-remitting MS, and many patients do not respond to any available therapy. A wide range of medications have been used to try to slow the progression of the disease.</p>
<p><a href="Mitoxantrone" class="uri" title="wikilink">Mitoxantrone</a> has shown positive effects in patients with a secondary progressive and progressive relapsing courses. It is moderately effective in reducing the progression of the disease and the frequency of relapses in patients in short-term follow-up.<a href="#fn26" class="footnote-ref" id="fnref26"><sup>26</sup></a> In 2007 it was the only medication approved for secondary progressive and progressive relapsing multiple sclerosis; however, it causes dose-dependent <a href="cardiotoxicity" title="wikilink">cardiac toxicity</a> which limits its long-term use. Interferon-beta-1b slowed progression of the disease in one clinical trial for secondary progressive MS, but not in another. However, both studies demonstrated that interferon recipients had fewer relapses and less disease activity, as assessed by <a href="magnetic_resonance_imaging" title="wikilink">magnetic resonance imaging</a> (MRI). Therefore, interferons show promise in treating secondary progressive MS, but more data is needed to support their widespread use.<a href="#fn27" class="footnote-ref" id="fnref27"><sup>27</sup></a></p>
<p>Several trials have been designed specifically for primary progressive multiple sclerosis (PPMS), including trials with <a href="interferon" title="wikilink">interferons</a> and <a href="mitoxantrone" class="uri" title="wikilink">mitoxantrone</a>, a phase III trial of <a href="glatiramer_acetate" title="wikilink">glatiramer acetate</a>, and an open-label study of <a href="riluzole" class="uri" title="wikilink">riluzole</a>.<a href="#fn28" class="footnote-ref" id="fnref28"><sup>28</sup></a> Patients with PPMS have also been included in trials of <a href="azathioprine" class="uri" title="wikilink">azathioprine</a>,<a href="#fn29" class="footnote-ref" id="fnref29"><sup>29</sup></a> <a href="methotrexate" class="uri" title="wikilink">methotrexate</a>,<a href="#fn30" class="footnote-ref" id="fnref30"><sup>30</sup></a> <a href="cladribine" class="uri" title="wikilink">cladribine</a>,<a href="#fn31" class="footnote-ref" id="fnref31"><sup>31</sup></a> <a href="intravenous_immunoglobulin" title="wikilink">intravenous immunoglobulin</a>, <a href="cyclophosphamide" class="uri" title="wikilink">cyclophosphamide</a>,<a href="#fn32" class="footnote-ref" id="fnref32"><sup>32</sup></a> and studies of <a href="Hematopoietic_stem_cell" title="wikilink">haematopoietic</a> <a href="stem_cell_transplantation" title="wikilink">stem cell transplantation</a>. However, no treatment in these trials has been proven definitively to modify the course of the disease.<a href="#fn33" class="footnote-ref" id="fnref33"><sup>33</sup></a></p>
<h3 id="side-effects-of-treatments">Side effects of treatments</h3>
<p>Both the <a href="interferon" title="wikilink">interferons</a> and <a href="glatiramer_acetate" title="wikilink">glatiramer acetate</a> are available only in injectable forms, and both can cause irritation at the injection site.</p>
<p><a href="Interferon" title="wikilink">Interferons</a> are produced in the body during illnesses such as <a href="influenza" class="uri" title="wikilink">influenza</a> in order to help fight the infection.<a href="#fn34" class="footnote-ref" id="fnref34"><sup>34</sup></a> They are responsible for the <a href="fever" class="uri" title="wikilink">fever</a>, <a href="myalgia" title="wikilink">muscle aches</a>, <a href="fatigue_(medical)" title="wikilink">fatigue</a>, and <a href="headache" class="uri" title="wikilink">headache</a> common during influenza infections. Many patients report influenza-like symptoms when using interferon to fight MS. This reaction often lessens over time and can be treated with over-the-counter fever reducers/pain relievers like <a href="paracetamol" class="uri" title="wikilink">paracetamol</a> (known in the U.S. as acetaminophen),<a href="#fn35" class="footnote-ref" id="fnref35"><sup>35</sup></a> <a href="ibuprofen" class="uri" title="wikilink">ibuprofen</a>,<a href="#fn36" class="footnote-ref" id="fnref36"><sup>36</sup></a> and <a href="naproxen" class="uri" title="wikilink">naproxen</a>.<a href="#fn37" class="footnote-ref" id="fnref37"><sup>37</sup></a> Rare, but potentially serious, <a href="liver" class="uri" title="wikilink">liver</a> function abnormalities have also been reported with interferons, requiring that all patients treated regularly be monitored with <a href="liver_function_tests" title="wikilink">liver function tests</a> to ensure safe use.<a href="#fn38" class="footnote-ref" id="fnref38"><sup>38</sup></a><a href="#fn39" class="footnote-ref" id="fnref39"><sup>39</sup></a><a href="#fn40" class="footnote-ref" id="fnref40"><sup>40</sup></a> Interferon therapy has also been shown to induce the production of anti-IFN neutralizing <a href="antibodies" class="uri" title="wikilink">antibodies</a> (NAb), usually in the second 6 months of treatment, in 3 to 45% of treated patients. However, the clinical consequences of the presence of antibodies are presently unclear: it has not been proved that these antibodies reduce efficacy of treatment. Therefore, any treatment decision should be based only on the clinical response to therapy.<a href="#fn41" class="footnote-ref" id="fnref41"><sup>41</sup></a></p>
<p><a href="Glatiramer_acetate" title="wikilink">Glatiramer acetate</a> is generally considered to be better tolerated than the interferons, although some patients taking glatiramer experience a post-injection reaction manifested by flushing, chest tightness, heart <a href="palpitation" title="wikilink">palpitations</a>, breathlessness, and anxiety, which usually lasts less than thirty minutes.<a href="#fn42" class="footnote-ref" id="fnref42"><sup>42</sup></a></p>
<p><a href="Mitoxantrone" class="uri" title="wikilink">Mitoxantrone</a> therapy may be associated with immunosuppressive effects and <a href="hepatotoxicity" title="wikilink">liver damage</a>; however its most dangerous side effect is its dose-related <a href="cardiotoxicity" title="wikilink">cardiac toxicity</a>. Careful adherence to the administration and monitoring <a href="guideline_(medical)" title="wikilink">guidelines</a> is therefore essential; this includes obtaining an <a href="echocardiogram" class="uri" title="wikilink">echocardiogram</a> and a <a href="complete_blood_count" title="wikilink">complete blood count</a> before treatment to decide whether the therapy is suitable for the patient or the risks are too great. It is recommended that mitoxantrone be discontinued at the first signs of heart damage, <a href="infection" class="uri" title="wikilink">infection</a> or liver dysfunction during therapy.<a href="#fn43" class="footnote-ref" id="fnref43"><sup>43</sup></a></p>
<p>In <a href="clinical_trial" title="wikilink">phase III studies</a>, <a href="natalizumab" class="uri" title="wikilink">natalizumab</a> was highly effective and well tolerated; however, three cases of <a href="progressive_multifocal_leukoencephalopathy" title="wikilink">progressive multifocal leukoencephalopathy</a> (PML) were identified in patients who had taken it in combination with interferons.<a href="#fn44" class="footnote-ref" id="fnref44"><sup>44</sup></a><a href="#fn45" class="footnote-ref" id="fnref45"><sup>45</sup></a> PML is a rare and progressive <a href="demyelinating" class="uri" title="wikilink">demyelinating</a> disease of the <a href="brain" class="uri" title="wikilink">brain</a> that typically causes permanent disability or death. It is caused by <a href="infection" class="uri" title="wikilink">infection</a> by the <a href="JC_virus" title="wikilink">JC virus</a> (JCV), a virus thought to be present in most healthy individuals, and at first its symptoms may be similar to a MS relapse. There are no known treatments for PML; but the sooner the <a href="immune_system" title="wikilink">immune system</a> returns to normal the higher the probabilities for recovery will be. As natalizumab was the suspected cause for these three cases of PML, it was withdrawn from the markets. An intensive safety evaluation was conducted which concluded that there was a potential risk of PML in patients taking natalizumab in combination with interferons. In 2006, natalizumab was finally re-approved as a monotherapy for patients with relapsing forms of MS.<a href="#fn46" class="footnote-ref" id="fnref46"><sup>46</sup></a></p>
<h2 id="management-of-the-effects-of-ms">Management of the effects of MS</h2>
<p>Disease-modifying treatments only reduce the progression rate of the disease but do not stop it. As multiple sclerosis progresses, the symptomatology tends to increase; the disease is associated with a variety of symptoms and functional deficits that result in a range of progressive impairments and <a href="Disability" title="wikilink">handicap</a>. Management of these deficits is therefore very important.</p>
<p>Both drug therapy and <a href="neurorehabilitation" class="uri" title="wikilink">neurorehabilitation</a> have shown to ease the burden of some symptoms, even though neither influences disease progression. For other symptoms the efficacy of treatments is still very limited.<a href="#fn47" class="footnote-ref" id="fnref47"><sup>47</sup></a></p>
<h3 id="neurorehabilitation">Neurorehabilitation</h3>
<figure>
<img src="LegExtensionMachineExercise.JPG" title="Supervised physical therapy may be helpful to overcome some symptoms." alt="Supervised physical therapy may be helpful to overcome some symptoms." /><figcaption>Supervised physical therapy may be helpful to overcome some symptoms.</figcaption>
</figure>
<p>Although there are few studies of rehabilitation in MS,<a href="#fn48" class="footnote-ref" id="fnref48"><sup>48</sup></a><a href="#fn49" class="footnote-ref" id="fnref49"><sup>49</sup></a> its general effectiveness, when conducted by a team of specialists, has been clearly demonstrated in other pathologies such as <a href="stroke" class="uri" title="wikilink">stroke</a><a href="#fn50" class="footnote-ref" id="fnref50"><sup>50</sup></a> or <a href="head_trauma" title="wikilink">head trauma</a>.<a href="#fn51" class="footnote-ref" id="fnref51"><sup>51</sup></a> As for any patient with neurologic deficits, a <a href="multidisciplinary" class="uri" title="wikilink">multidisciplinary</a> approach is key to limiting and overcoming disability; however there are particular difficulties in specifying a &lt;U+2018&gt;core team&lt;U+2019&gt; because people with MS may need help from almost any health profession or service at some point.<a href="#fn52" class="footnote-ref" id="fnref52"><sup>52</sup></a> <a href="Neurologist" title="wikilink">Neurologists</a> will be the main <a href="physician" title="wikilink">physicians</a> involved, but depending on the symptom, doctors of other medical specialties may also be helpful. Allied treatments such as <a href="physical_therapy" title="wikilink">physical therapy</a><a href="#fn53" class="footnote-ref" id="fnref53"><sup>53</sup></a><a href="#fn54" class="footnote-ref" id="fnref54"><sup>54</sup></a> or <a href="speech_therapy" title="wikilink">speech therapy</a><a href="#fn55" class="footnote-ref" id="fnref55"><sup>55</sup></a> can also help to manage some symptoms and maintain <a href="quality_of_life" title="wikilink">quality of life</a>. Treatment of <a href="neuropsychiatry" title="wikilink">neuropsychiatric</a> symptoms such as emotional distress and <a href="clinical_depression" title="wikilink">clinical depression</a> should involve <a href="mental_health" title="wikilink">mental health</a> professionals such as <a href="therapist" title="wikilink">therapists</a>, <a href="psychologist" title="wikilink">psychologists</a>, and <a href="psychiatrist" title="wikilink">psychiatrists</a>,<a href="#fn56" class="footnote-ref" id="fnref56"><sup>56</sup></a> while <a href="neuropsychologist" title="wikilink">neuropsychologists</a> can help to evaluate and manage <a href="cognitive_deficit" title="wikilink">cognitive deficits</a>.<a href="#fn57" class="footnote-ref" id="fnref57"><sup>57</sup></a> Although <a href="occupational_therapy" title="wikilink">occupational therapy</a> has shown its efficacy in other chronic neurologic conditions<a href="#fn58" class="footnote-ref" id="fnref58"><sup>58</sup></a> and some preliminary data suggests that it may be useful in MS,<a href="#fn59" class="footnote-ref" id="fnref59"><sup>59</sup></a> there are not sufficient randomized controlled studies to establish its effectiveness.<a href="#fn60" class="footnote-ref" id="fnref60"><sup>60</sup></a><a href="#fn61" class="footnote-ref" id="fnref61"><sup>61</sup></a></p>
<h3 id="medical-treatments-for-symptoms">Medical treatments for symptoms</h3>

<p>Multiple sclerosis can cause a variety of symptoms including changes in sensation (<a href="hypoesthesia" class="uri" title="wikilink">hypoesthesia</a>), muscle weakness, abnormal muscle spasms, difficulty to move, difficulties with coordination and balance, problems in speech (known as <a href="dysarthria" class="uri" title="wikilink">dysarthria</a>) or swallowing (<a href="dysphagia" class="uri" title="wikilink">dysphagia</a>), visual problems (<a href="nystagmus" class="uri" title="wikilink">nystagmus</a>, <a href="optic_neuritis" title="wikilink">optic neuritis</a>, or <a href="diplopia" class="uri" title="wikilink">diplopia</a>), <a href="fatigue_(medical)" title="wikilink">fatigue</a> and acute or chronic <a href="pain" class="uri" title="wikilink">pain</a> syndromes, <a href="Urinary_bladder" title="wikilink">bladder</a> and <a href="bowel" class="uri" title="wikilink">bowel</a> difficulties, cognitive impairment, or emotional symptomatology (mainly <a href="clinical_depression" title="wikilink">depression</a>). The main clinical measure of disability progression and severity of the symptoms is the <a href="Expanded_Disability_Status_Scale" title="wikilink">Expanded Disability Status Scale</a> or EDSS.<a href="#fn62" class="footnote-ref" id="fnref62"><sup>62</sup></a> At the same time for each symptom there are different treatment options. Treatments should therefore be individualized depending both on the patient and the physician.</p>
<ul>
<li><strong>Bladder</strong>: pharmacological treatments for bladder problems vary greatly depending on the origin or type of dysfunction; however, some examples of medications used are:<a href="#fn63" class="footnote-ref" id="fnref63"><sup>63</sup></a> <a href="alfuzosin" class="uri" title="wikilink">alfuzosin</a> for retention,<a href="#fn64" class="footnote-ref" id="fnref64"><sup>64</sup></a> <a href="anticholinergic" title="wikilink">anticholinergics</a> such as <a href="trospium" class="uri" title="wikilink">trospium</a> and <a href="flavoxate" class="uri" title="wikilink">flavoxate</a> for <a href="urinary_urgency" title="wikilink">urgency</a> and <a href="urinary_incontinence" title="wikilink">incontinence</a>,<a href="#fn65" class="footnote-ref" id="fnref65"><sup>65</sup></a><a href="#fn66" class="footnote-ref" id="fnref66"><sup>66</sup></a> or <a href="desmopressin" class="uri" title="wikilink">desmopressin</a> for <a href="nocturia" class="uri" title="wikilink">nocturia</a>.<a href="#fn67" class="footnote-ref" id="fnref67"><sup>67</sup></a><a href="#fn68" class="footnote-ref" id="fnref68"><sup>68</sup></a> Non-pharmacological treatments involve the use of <a href="pelvic_floor" title="wikilink">pelvic floor</a> muscle training, stimulation, <a href="biofeedback" class="uri" title="wikilink">biofeedback</a>, <a href="pessary" title="wikilink">pessaries</a>, bladder retraining, and sometimes intermittent <a href="urinary_catheterization" title="wikilink">catheterization</a>.<a href="#fn69" class="footnote-ref" id="fnref69"><sup>69</sup></a></li>
</ul>
<ul>
<li><strong>Bowel</strong>: people with MS may suffer bowel problems in two ways: reduced gut mobility may follow from immobility and the drugs used to treat various impairments; and neurological control of <a href="defecation" class="uri" title="wikilink">defecation</a> may be directly impaired.<a href="#fn70" class="footnote-ref" id="fnref70"><sup>70</sup></a> Pain or difficulty with defecation can be helped with a diet change, oral <a href="laxative" title="wikilink">laxatives</a> or <a href="suppository" title="wikilink">suppositories</a> and <a href="enema" title="wikilink">enemas</a>.<a href="#fn71" class="footnote-ref" id="fnref71"><sup>71</sup></a></li>
</ul>
<ul>
<li><strong>Cognitive and emotional</strong>: <a href="Neuropsychiatry" title="wikilink">neuropsychiatric</a> symptomatology is not rare in the course of the disease. Depression and <a href="anxiety" class="uri" title="wikilink">anxiety</a> appear in up to 80% of patients,<a href="#fn72" class="footnote-ref" id="fnref72"><sup>72</sup></a> and can be treated with a variety of antidepressants;<a href="#fn73" class="footnote-ref" id="fnref73"><sup>73</sup></a> <a href="selective_serotonin_reuptake_inhibitor" title="wikilink">selective serotonin reuptake inhibitors</a> (SSRIs) are the most commonly employed.<a href="#fn74" class="footnote-ref" id="fnref74"><sup>74</sup></a> Other neuropsychiatric symptoms are <a href="euphoria_(emotion)" title="wikilink">euphoria</a> and <a href="disinhibition" class="uri" title="wikilink">disinhibition</a>. This <a href="wikt:dyad" title="wikilink">dyad</a> was called &quot;euphoria sclerotica&quot; by the first authors that described the disease during the 19th century, and affects 10% of patients.<a href="#fn75" class="footnote-ref" id="fnref75"><sup>75</sup></a><a href="#fn76" class="footnote-ref" id="fnref76"><sup>76</sup></a> On the other hand, <a href="cognitive_deficit" title="wikilink">cognitive deficits</a> appear in approximately 50% of the people with the disease.<a href="#fn77" class="footnote-ref" id="fnref77"><sup>77</sup></a> <a href="Anticholinesterase" class="uri" title="wikilink">Anticholinesterase</a> drugs such as <a href="donepezil" class="uri" title="wikilink">donepezil</a><a href="#fn78" class="footnote-ref" id="fnref78"><sup>78</sup></a>&lt;U+2014&gt;commonly used in <a href="Alzheimer_disease" title="wikilink">Alzheimer disease</a>&lt;U+2014&gt;although not approved yet for multiple sclerosis, have shown efficacy in improving cognitive functions.<a href="#fn79" class="footnote-ref" id="fnref79"><sup>79</sup></a><a href="#fn80" class="footnote-ref" id="fnref80"><sup>80</sup></a> Psychological interventions are also useful in the treatment of cognitive and emotional deficits.<a href="#fn81" class="footnote-ref" id="fnref81"><sup>81</sup></a><a href="#fn82" class="footnote-ref" id="fnref82"><sup>82</sup></a><a href="#fn83" class="footnote-ref" id="fnref83"><sup>83</sup></a><a href="#fn84" class="footnote-ref" id="fnref84"><sup>84</sup></a></li>
</ul>
<ul>
<li><strong>Dysphagia and dysarthria</strong>: <a href="dysphagia" class="uri" title="wikilink">dysphagia</a> is a difficulty with swallowing which may cause <a href="choking" class="uri" title="wikilink">choking</a> and <a href="pulmonary_aspiration" title="wikilink">aspiration</a> of food or liquid into the <a href="lung" title="wikilink">lungs</a>, while <a href="dysarthria" class="uri" title="wikilink">dysarthria</a> is a <a href="neurological" class="uri" title="wikilink">neurological</a> motor <a href="speech_disorder" title="wikilink">speech disorder</a> characterized by poor control over the subsystems and muscles responsible for <a href="speech_communication" title="wikilink">speech</a> (&quot;articulation&quot;). A language therapist may give advice on specific swallowing techniques, on adapting food consistencies and dietary intake, on techniques to improve and maintain speech production and clarity, and on alternative communication systems.<a href="#fn85" class="footnote-ref" id="fnref85"><sup>85</sup></a><a href="#fn86" class="footnote-ref" id="fnref86"><sup>86</sup></a> In the case of advanced dysphagia, food can be supplied by a <a href="feeding_tube" title="wikilink">nasogastric tube</a>, which is a tube that goes through the nose directly to the stomach; or a <a href="percutaneous_endoscopic_gastrostomy" title="wikilink">percutaneous endoscopic gastrostomy</a> (PEG), which is a procedure for placing a tube into the stomach and therefore administering food directly to it. This second system, although more <a href="Invasive_(medical)" title="wikilink">invasive</a>, has better results in the long term than nasogastric intake.<a href="#fn87" class="footnote-ref" id="fnref87"><sup>87</sup></a></li>
</ul>
<ul>
<li><strong>Fatigue</strong>: <a href="fatigue_(medical)" title="wikilink">fatigue</a> is very common and disabling in MS, and at the same time it has a close relationship with depressive symptomatology.<a href="#fn88" class="footnote-ref" id="fnref88"><sup>88</sup></a> When depression is reduced fatigue also tends to improve, so patients should be evaluated for depression before other therapeutic approaches are used.<a href="#fn89" class="footnote-ref" id="fnref89"><sup>89</sup></a> In a similar way, other factors such as disturbed sleep, chronic pain, poor nutrition, or even some medications can contribute to fatigue; medical professionals are therefore encouraged to identify and modify them.<a href="#fn90" class="footnote-ref" id="fnref90"><sup>90</sup></a> There are also different medications used to treat fatigue, such as <a href="amantadine" class="uri" title="wikilink">amantadine</a><a href="#fn91" class="footnote-ref" id="fnref91"><sup>91</sup></a><a href="#fn92" class="footnote-ref" id="fnref92"><sup>92</sup></a> or <a href="pemoline" class="uri" title="wikilink">pemoline</a>,<a href="#fn93" class="footnote-ref" id="fnref93"><sup>93</sup></a><a href="#fn94" class="footnote-ref" id="fnref94"><sup>94</sup></a> as well as psychological interventions of energy conservation,<a href="#fn95" class="footnote-ref" id="fnref95"><sup>95</sup></a><a href="#fn96" class="footnote-ref" id="fnref96"><sup>96</sup></a> but the effects of all of them are small. Fatigue is therefore a very difficult symptom to manage.</li>
</ul>
<ul>
<li><strong>Pain</strong>: <a href="acute_(medical)" title="wikilink">acute</a> pain is mainly due to <a href="optic_neuritis" title="wikilink">optic neuritis</a> (with <a href="corticosteroids" class="uri" title="wikilink">corticosteroids</a> being the best treatment available), as well as <a href="trigeminal_neuralgia" title="wikilink">trigeminal neuralgia</a>, <a href="Lhermitte&#39;s_sign" title="wikilink">Lhermitte's sign</a>, or <a href="dysesthesias" class="uri" title="wikilink">dysesthesias</a>.<a href="#fn97" class="footnote-ref" id="fnref97"><sup>97</sup></a> <a href="Subacute" class="uri" title="wikilink">Subacute</a> pain is usually secondary to the disease and can be a consequence of spending too long in the same position, urinary retention, and infected skin ulcers, amongst others. Treatment will depend on cause. <a href="Chronic_(medicine)" title="wikilink">Chronic</a> pain is very common and harder to treat as its most common cause is dysesthesias. Acute pain due to trigeminal neuralgia is usually successfully treated with anticonvulsants such as <a href="carbamazepine" class="uri" title="wikilink">carbamazepine</a><a href="#fn98" class="footnote-ref" id="fnref98"><sup>98</sup></a> or <a href="phenytoin" class="uri" title="wikilink">phenytoin</a>.<a href="#fn99" class="footnote-ref" id="fnref99"><sup>99</sup></a><a href="#fn100" class="footnote-ref" id="fnref100"><sup>100</sup></a><a href="#fn101" class="footnote-ref" id="fnref101"><sup>101</sup></a> Both Lhermitte's sign and painful dysesthesias usually respond to treatment with <a href="carbamazepine" class="uri" title="wikilink">carbamazepine</a>, <a href="clonazepam" class="uri" title="wikilink">clonazepam</a>,<a href="#fn102" class="footnote-ref" id="fnref102"><sup>102</sup></a> or <a href="amitriptyline" class="uri" title="wikilink">amitriptyline</a>.<a href="#fn103" class="footnote-ref" id="fnref103"><sup>103</sup></a><a href="#fn104" class="footnote-ref" id="fnref104"><sup>104</sup></a> <a href="Sativex" class="uri" title="wikilink">Sativex</a> is approved for treatment of pain in MS in different countries, but due to its derivation from <a href="cannabis" class="uri" title="wikilink">cannabis</a>, it is currently not available in others, such as the USA.<a href="#fn105" class="footnote-ref" id="fnref105"><sup>105</sup></a> This medication is also being investigated for the management of other MS symptoms, such as spasticity,<a href="#fn106" class="footnote-ref" id="fnref106"><sup>106</sup></a> and has shown long-term safety and efficacy.<a href="#fn107" class="footnote-ref" id="fnref107"><sup>107</sup></a></li>
</ul>
<ul>
<li><strong>Spasticity</strong>: <a href="spasticity" class="uri" title="wikilink">spasticity</a> is characterised by increased stiffness and slowness in <a href="Limb_(anatomy)" title="wikilink">limb</a> movement, the development of certain postures, an association with weakness of voluntary <a href="muscle" class="uri" title="wikilink">muscle</a> power, and with involuntary and sometimes painful <a href="spasm" title="wikilink">spasms</a> of limbs.<a href="#fn108" class="footnote-ref" id="fnref108"><sup>108</sup></a> A physiotherapist can help to reduce spasticity and avoid the development of <a href="contracture" title="wikilink">contractures</a> with techniques such as <a href="passive_stretching" title="wikilink">passive stretching</a>.<a href="#fn109" class="footnote-ref" id="fnref109"><sup>109</sup></a> There is evidence, albeit limited, of the clinical effectiveness of <a href="baclofen" class="uri" title="wikilink">baclofen</a>,<a href="#fn110" class="footnote-ref" id="fnref110"><sup>110</sup></a> <a href="dantrolene" class="uri" title="wikilink">dantrolene</a>,<a href="#fn111" class="footnote-ref" id="fnref111"><sup>111</sup></a> <a href="diazepam" class="uri" title="wikilink">diazepam</a>,<a href="#fn112" class="footnote-ref" id="fnref112"><sup>112</sup></a> and <a href="tizanidine" class="uri" title="wikilink">tizanidine</a>.<a href="#fn113" class="footnote-ref" id="fnref113"><sup>113</sup></a><a href="#fn114" class="footnote-ref" id="fnref114"><sup>114</sup></a><a href="#fn115" class="footnote-ref" id="fnref115"><sup>115</sup></a> In the most complicated cases <a href="intrathecal" class="uri" title="wikilink">intrathecal</a> injections of baclofen can be used.<a href="#fn116" class="footnote-ref" id="fnref116"><sup>116</sup></a> There are also <a href="palliative" class="uri" title="wikilink">palliative</a> measures like <a href="casting" title="wikilink">castings</a>, <a href="splint_(medical)" title="wikilink">splints</a> or customised seatings.<a href="#fn117" class="footnote-ref" id="fnref117"><sup>117</sup></a></li>
</ul>
<ul>
<li><strong>Vision</strong>: different drugs as well as optic compensatory systems and prisms can be used to improve the symptoms of <a href="nystagmus" class="uri" title="wikilink">nystagmus</a>.<a href="#fn118" class="footnote-ref" id="fnref118"><sup>118</sup></a><a href="#fn119" class="footnote-ref" id="fnref119"><sup>119</sup></a><a href="#fn120" class="footnote-ref" id="fnref120"><sup>120</sup></a> Surgery can also be used in some cases for this problem.<a href="#fn121" class="footnote-ref" id="fnref121"><sup>121</sup></a></li>
</ul>
<p>Unfortunately, other symptoms, such as <a href="ataxia" class="uri" title="wikilink">ataxia</a>, <a href="tremor" class="uri" title="wikilink">tremor</a> or <a href="sensory_system" title="wikilink">sensory losses</a>, do not have proven treatments.<a href="#fn122" class="footnote-ref" id="fnref122"><sup>122</sup></a></p>
<h2 id="therapies-under-investigation">Therapies under investigation</h2>

<p>Scientists continue their extensive efforts to create new and better therapies for MS. There are a number of treatments under investigation that may curtail attacks or improve function. Some of these treatments involve the combination of drugs that are already in use for multiple sclerosis, such as the combination of <a href="mitoxantrone" class="uri" title="wikilink">mitoxantrone</a> and <a href="glatiramer_acetate" title="wikilink">glatiramer acetate</a> (<em>Copaxone</em>).<a href="#fn123" class="footnote-ref" id="fnref123"><sup>123</sup></a> However most treatments already in clinical trials involve drugs that are used in other diseases. These are the cases of <a href="alemtuzumab" class="uri" title="wikilink">alemtuzumab</a> (trade name <em>Campath</em>),<a href="#fn124" class="footnote-ref" id="fnref124"><sup>124</sup></a> <a href="daclizumab" class="uri" title="wikilink">daclizumab</a> (trade name <em>Zenapax</em>),<a href="#fn125" class="footnote-ref" id="fnref125"><sup>125</sup></a> <a href="inosine" class="uri" title="wikilink">inosine</a>,<a href="#fn126" class="footnote-ref" id="fnref126"><sup>126</sup></a> or <a href="BG00012" class="uri" title="wikilink">BG00012</a>.<a href="#fn127" class="footnote-ref" id="fnref127"><sup>127</sup></a> Other drugs in clinical trials have been designed specifically for MS, like <a href="fingolimod" class="uri" title="wikilink">fingolimod</a>,<a href="#fn128" class="footnote-ref" id="fnref128"><sup>128</sup></a> <a href="laquinimod" class="uri" title="wikilink">laquinimod</a>,<a href="#fn129" class="footnote-ref" id="fnref129"><sup>129</sup></a> or <em><a href="Neurovax" class="uri" title="wikilink">Neurovax</a></em>.<a href="#fn130" class="footnote-ref" id="fnref130"><sup>130</sup></a> Finally, there are also many basic investigations that in the future may be able to find new treatments. Examples of these are the studies trying to understand the influence of <em><a href="Chlamydophila_pneumoniae" title="wikilink">Chlamydophila pneumoniae</a></em> or <a href="vitamin_D" title="wikilink">vitamin D</a> in the origin of the disease,<a href="#fn131" class="footnote-ref" id="fnref131"><sup>131</sup></a><a href="#fn132" class="footnote-ref" id="fnref132"><sup>132</sup></a> or preliminary investigations on the use of <a href="helminthic_therapy" title="wikilink">helminthic therapy</a>.<a href="#fn133" class="footnote-ref" id="fnref133"><sup>133</sup></a></p>
<h2 id="alternative-treatments">Alternative treatments</h2>
<p><img src="Cannabis_sativa.jpg" title="fig:Many patients use medical marijuana as an alternative treatment to help them alleviate some symptoms." alt="Many patients use medical marijuana as an alternative treatment to help them alleviate some symptoms." /> Different alternative treatments are pursued by many patients, despite the paucity of supporting, comparable, replicated scientific study.</p>
<p>Clinical and experimental data suggest that certain <a href="Diet_(nutrition)" title="wikilink">dietary</a> regimens, particularly those including <a href="polyunsaturated_fatty_acid" title="wikilink">polyunsaturated fatty acids</a>, and <a href="vitamin" title="wikilink">vitamins</a> might improve outcomes in people with multiple sclerosis.<a href="#fn134" class="footnote-ref" id="fnref134"><sup>134</sup></a><a href="#fn135" class="footnote-ref" id="fnref135"><sup>135</sup></a> Many diets have been proposed for treating the symptoms of the disease. Patients have reported a decrease in symptoms after long-term application of changes in diet; however, no controlled trials have been able to prove their efficacy.<a href="#fn136" class="footnote-ref" id="fnref136"><sup>136</sup></a> Even if these diets are genuinely beneficial for people with MS, it is uncertain whether this is due to any special traits of the diets or that they are simply beneficial for whole body health. Two examples of such diets are the <a href="Swank_Multiple_Sclerosis_Diet" title="wikilink">Swank Multiple Sclerosis Diet</a><a href="#fn137" class="footnote-ref" id="fnref137"><sup>137</sup></a><a href="#fn138" class="footnote-ref" id="fnref138"><sup>138</sup></a> and the <a href="Best_Bet_Diet_(multiple_sclerosis)" title="wikilink">Best Bet Diet</a>.<a href="#fn139" class="footnote-ref" id="fnref139"><sup>139</sup></a></p>
<p><a href="Herbal_medicine" title="wikilink">Herbal medicine</a> is another source of alternative treatments. Many patients use medical <a href="marijuana" class="uri" title="wikilink">marijuana</a> to help alleviate symptoms; however, the results of experimental studies are scarce. At least one subgroup experiencing greater disability appears to have derived some symptomatic benefit.<a href="#fn140" class="footnote-ref" id="fnref140"><sup>140</sup></a><a href="#fn141" class="footnote-ref" id="fnref141"><sup>141</sup></a></p>
<p><a href="Hyperbaric_oxygenation" title="wikilink">Hyperbaric oxygenation</a> has been the subject of several small studies with heterogeneous results which, overall, do not support its use.<a href="#fn142" class="footnote-ref" id="fnref142"><sup>142</sup></a></p>
<p>The <a href="Martial_arts_therapy" title="wikilink">therapeutic practice of martial arts</a> such as <a href="tai_chi" title="wikilink">tai chi</a>, relaxation disciplines such as <a href="yoga" class="uri" title="wikilink">yoga</a>, or general exercise, seem to mitigate fatigue and improve quality of life.<a href="#fn143" class="footnote-ref" id="fnref143"><sup>143</sup></a> Some studies also show benefits on physical variables but more investigation is needed as they are usually of low quality.<a href="#fn144" class="footnote-ref" id="fnref144"><sup>144</sup></a></p>
<h2 id="further-reading">Further reading</h2>
<p><strong>Clinical guidelines</strong>: <a href="clinical_guideline" title="wikilink">clinical guidelines</a> are documents with the aim of guiding decisions and criteria in specific areas of healthcare, as defined by an authoritative examination of current evidence (<a href="evidence-based_medicine" title="wikilink">evidence-based medicine</a>).</p>
<ul>
<li><p><a href="http://www.rcplondon.ac.uk/pubs/books/MS/MSfulldocument.pdf">Free full text</a> (<a href="2004-08-13" class="uri" title="wikilink">2004-08-13</a>). Retrieved on <a href="2007-10-01" class="uri" title="wikilink">2007-10-01</a>.</p></li>
<li><p><a href="http://guidance.nice.org.uk/CG8/publicinfo/pdf/English/download.dspx">Free full text</a> (<a href="2003-11-26" class="uri" title="wikilink">2003-11-26</a>). Retrieved on <a href="2007-10-25" class="uri" title="wikilink">2007-10-25</a>.</p></li>
</ul>
<h2 id="notes-and-references">Notes and references</h2>


<p><a href="es:Tratamiento_de_la_esclerosis_m&lt;U+00FA&gt;ltiple" title="wikilink">es:Tratamiento de la esclerosis m&lt;U+00FA&gt;ltiple</a></p>
<p><a href="Category:Autoimmune_diseases" title="wikilink">Category:Autoimmune diseases</a> <a href="Category:Multiple_sclerosis" title="wikilink">Category:Multiple sclerosis</a> <a href="Category:Medical_treatments" title="wikilink">Category:Medical treatments</a> <a href="Category:Neurological_disorders" title="wikilink">Category:Neurological disorders</a></p>
<section class="footnotes">
<hr />
<ol>
<li id="fn1"><a href="http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682795.html">Methylprednisolone Oral.</a> US National Library of Medicine (Medline) (<a href="2003-04-01" class="uri" title="wikilink">2003-04-01</a>). Retrieved on <a href="2007-09-01" class="uri" title="wikilink">2007-09-01</a>.<a href="#fnref1" class="footnote-back">↩</a></li>
<li id="fn2"><a href="http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a601157.html">Methylprednisolone Sodium Succinate Injection.</a> US National Library of Medicine (Medline) (<a href="2003-04-01" class="uri" title="wikilink">2003-04-01</a>). Retrieved on <a href="2007-09-01" class="uri" title="wikilink">2007-09-01</a>.<a href="#fnref2" class="footnote-back">↩</a></li>
<li id="fn3"><a href="#fnref3" class="footnote-back">↩</a></li>
<li id="fn4"><a href="#fnref4" class="footnote-back">↩</a></li>
<li id="fn5"><a href="#fnref5" class="footnote-back">↩</a></li>
<li id="fn6"><a href="#fnref6" class="footnote-back">↩</a></li>
<li id="fn7"><a href="#fnref7" class="footnote-back">↩</a></li>
<li id="fn8"><a href="#fnref8" class="footnote-back">↩</a></li>
<li id="fn9"><a href="#fnref9" class="footnote-back">↩</a></li>
<li id="fn10"><a href="#fnref10" class="footnote-back">↩</a></li>
<li id="fn11"><a href="http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a693040.html">Interferon beta-1a Intramuscular Injection.</a> US National Library of Medicine (Medline) (<a href="2006-04-01" class="uri" title="wikilink">2006-04-01</a>). Retrieved on <a href="2007-09-02" class="uri" title="wikilink">2007-09-02</a>.<a href="#fnref11" class="footnote-back">↩</a></li>
<li id="fn12"><a href="http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a604005.html">Interferon beta-1a Subcutaneous Injection.</a> US National Library of Medicine (Medline) (<a href="2004-04-01" class="uri" title="wikilink">2004-04-01</a>). Retrieved on <a href="2007-09-02" class="uri" title="wikilink">2007-09-02</a>.<a href="#fnref12" class="footnote-back">↩</a></li>
<li id="fn13"><a href="http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a601151.html">Interferon Beta-1b Injection.</a> US National Library of Medicine (Medline) (<a href="2005-07-01" class="uri" title="wikilink">2005-07-01</a>). Retrieved on <a href="2007-09-02" class="uri" title="wikilink">2007-09-02</a>.<a href="#fnref13" class="footnote-back">↩</a></li>
<li id="fn14"><a href="http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a603016.html">Glatiramer injection.</a> US National Library of Medicine (Medline) (<a href="2003-07-01" class="uri" title="wikilink">2003-07-01</a>). Retrieved on <a href="2007-09-02" class="uri" title="wikilink">2007-09-02</a>.<a href="#fnref14" class="footnote-back">↩</a></li>
<li id="fn15"><a href="#fnref15" class="footnote-back">↩</a></li>
<li id="fn16"><a href="http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a605006.html">Natalizumab Injection.</a> US National Library of Medicine (Medline) (<a href="2006-10-01" class="uri" title="wikilink">2006-10-01</a>). Retrieved on <a href="2007-09-02" class="uri" title="wikilink">2007-09-02</a>.<a href="#fnref16" class="footnote-back">↩</a></li>
<li id="fn17"><a href="#fnref17" class="footnote-back">↩</a></li>
<li id="fn18"><a href="#fnref18" class="footnote-back">↩</a></li>
<li id="fn19"><a href="#fnref19" class="footnote-back">↩</a></li>
<li id="fn20"><a href="http://www.peacehealth.org/kbase/dp/topic/tf2571/dp.htm">Should I have disease-modifying therapy for multiple sclerosis?</a> Peace Health (<a href="2006-03-23" class="uri" title="wikilink">2006-03-23</a>). Retrieved on <a href="2007-10-23" class="uri" title="wikilink">2007-10-23</a>.<a href="#fnref20" class="footnote-back">↩</a></li>
<li id="fn21"><a href="http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a605006.html">Natalizumab Injection.</a> US National Library of Medicine (Medline) (<a href="2006-10-01" class="uri" title="wikilink">2006-10-01</a>). Retrieved on <a href="2007-09-02" class="uri" title="wikilink">2007-09-02</a>.<a href="#fnref21" class="footnote-back">↩</a></li>
<li id="fn22"></li>
<li id="fn23"></li>
<li id="fn24"></li>
<li id="fn25"></li>
<li id="fn26"><a href="#fnref26" class="footnote-back">↩</a></li>
<li id="fn27"><a href="#fnref27" class="footnote-back">↩</a></li>
<li id="fn28"><a href="http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a696013.html">Riluzole.</a> US National Library of Medicine (Medline) (<a href="2003-04-01" class="uri" title="wikilink">2003-04-01</a>). Retrieved on <a href="2007-09-02" class="uri" title="wikilink">2007-09-02</a>.<a href="#fnref28" class="footnote-back">↩</a></li>
<li id="fn29"><a href="http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682167.html">Azathioprine.</a> US National Library of Medicine (Medline) (<a href="2004-04-01" class="uri" title="wikilink">2004-04-01</a>). Retrieved on <a href="2007-09-02" class="uri" title="wikilink">2007-09-02</a>.<a href="#fnref29" class="footnote-back">↩</a></li>
<li id="fn30"><a href="http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682019.html">Methotrexate.</a> US National Library of Medicine (Medline) (<a href="2006-10-01" class="uri" title="wikilink">2006-10-01</a>). Retrieved on <a href="2007-09-02" class="uri" title="wikilink">2007-09-02</a>.<a href="#fnref30" class="footnote-back">↩</a></li>
<li id="fn31"><a href="http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a693015.html">Cladribine.</a> US National Library of Medicine (Medline) (<a href="2003-04-01" class="uri" title="wikilink">2003-04-01</a>). Retrieved on <a href="2007-09-02" class="uri" title="wikilink">2007-09-02</a>.<a href="#fnref31" class="footnote-back">↩</a></li>
<li id="fn32"><a href="http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682080.html">Cyclophosphamide.</a> US National Library of Medicine (Medline) (<a href="2003-04-01" class="uri" title="wikilink">2003-04-01</a>). Retrieved on <a href="2007-09-02" class="uri" title="wikilink">2007-09-02</a>.<a href="#fnref32" class="footnote-back">↩</a></li>
<li id="fn33"><a href="#fnref33" class="footnote-back">↩</a></li>
<li id="fn34"><a href="#fnref34" class="footnote-back">↩</a></li>
<li id="fn35"><a href="http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a681004.html">Acetaminophen.</a> US National Library of Medicine (Medline) (<a href="2007-07-01" class="uri" title="wikilink">2007-07-01</a>). Retrieved on <a href="2007-09-02" class="uri" title="wikilink">2007-09-02</a>.<a href="#fnref35" class="footnote-back">↩</a></li>
<li id="fn36"><a href="http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682159.html">Ibuprofen.</a> US National Library of Medicine (Medline) (<a href="2007-03-01" class="uri" title="wikilink">2007-03-01</a>). Retrieved on <a href="2007-09-02" class="uri" title="wikilink">2007-09-02</a>.<a href="#fnref36" class="footnote-back">↩</a></li>
<li id="fn37"><a href="http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a681029.html">Naproxen.</a> US National Library of Medicine (Medline) (<a href="2006-01-01" class="uri" title="wikilink">2006-01-01</a>). Retrieved on <a href="2007-09-02" class="uri" title="wikilink">2007-09-02</a>.<a href="#fnref37" class="footnote-back">↩</a></li>
<li id="fn38">Betaseron [package insert]. Montville, NJ: Berlex Inc; 2003<a href="#fnref38" class="footnote-back">↩</a></li>
<li id="fn39">Rebif [package insert]. Rockland, MA: Serono Inc; 2005.<a href="#fnref39" class="footnote-back">↩</a></li>
<li id="fn40">Avonex [package insert]. Cambridge, MA: Biogen Inc; 2003<a href="#fnref40" class="footnote-back">↩</a></li>
<li id="fn41"><a href="#fnref41" class="footnote-back">↩</a></li>
<li id="fn42"><a href="#fnref42" class="footnote-back">↩</a></li>
<li id="fn43"><a href="#fnref43" class="footnote-back">↩</a></li>
<li id="fn44"> <a href="http://content.nejm.org/cgi/content/abstract/353/4/369">Free full text with registration</a><a href="#fnref44" class="footnote-back">↩</a></li>
<li id="fn45"> <a href="http://content.nejm.org/cgi/content/abstract/353/4/375">Free full text with registration</a><a href="#fnref45" class="footnote-back">↩</a></li>
<li id="fn46"><a href="#fnref46" class="footnote-back">↩</a></li>
<li id="fn47"><a href="#fnref47" class="footnote-back">↩</a></li>
<li id="fn48"><a href="#fnref48" class="footnote-back">↩</a></li>
<li id="fn49"><a href="#fnref49" class="footnote-back">↩</a></li>
<li id="fn50"><a href="#fnref50" class="footnote-back">↩</a></li>
<li id="fn51"><a href="#fnref51" class="footnote-back">↩</a></li>
<li id="fn52"><a href="http://www.rcplondon.ac.uk/pubs/books/MS/MSfulldocument.pdf">Free full text</a> (<a href="2004-08-13" class="uri" title="wikilink">2004-08-13</a>). Retrieved on <a href="2007-10-01" class="uri" title="wikilink">2007-10-01</a>.<a href="#fnref52" class="footnote-back">↩</a></li>
<li id="fn53"><a href="#fnref53" class="footnote-back">↩</a></li>
<li id="fn54"><a href="#fnref54" class="footnote-back">↩</a></li>
<li id="fn55"><a href="#fnref55" class="footnote-back">↩</a></li>
<li id="fn56"><a href="#fnref56" class="footnote-back">↩</a></li>
<li id="fn57"><a href="#fnref57" class="footnote-back">↩</a></li>
<li id="fn58"><a href="#fnref58" class="footnote-back">↩</a></li>
<li id="fn59"><a href="#fnref59" class="footnote-back">↩</a></li>
<li id="fn60"></li>
<li id="fn61"><a href="#fnref61" class="footnote-back">↩</a></li>
<li id="fn62"><a href="#fnref62" class="footnote-back">↩</a></li>
<li id="fn63"><a href="#fnref63" class="footnote-back">↩</a></li>
<li id="fn64"><a href="http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a604002.html">Alfuzosin.</a> US National Library of Medicine (Medline) (<a href="2007-03-01" class="uri" title="wikilink">2007-03-01</a>). Retrieved on <a href="2007-09-02" class="uri" title="wikilink">2007-09-02</a>.<a href="#fnref64" class="footnote-back">↩</a></li>
<li id="fn65"><a href="http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a604037.html">Trospium.</a> US National Library of Medicine (Medline) (<a href="2005-01-01" class="uri" title="wikilink">2005-01-01</a>). Retrieved on <a href="2007-09-02" class="uri" title="wikilink">2007-09-02</a>.<a href="#fnref65" class="footnote-back">↩</a></li>
<li id="fn66"><a href="http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682706.html">Flavoxate.</a> US National Library of Medicine (Medline) (<a href="2003-04-01" class="uri" title="wikilink">2003-04-01</a>). Retrieved on <a href="2007-09-02" class="uri" title="wikilink">2007-09-02</a>.<a href="#fnref66" class="footnote-back">↩</a></li>
<li id="fn67"><a href="#fnref67" class="footnote-back">↩</a></li>
<li id="fn68"><a href="http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682876.html">Desmopressin.</a> US National Library of Medicine (Medline) (<a href="2003-04-01" class="uri" title="wikilink">2003-04-01</a>). Retrieved on <a href="2007-09-02" class="uri" title="wikilink">2007-09-02</a>.<a href="#fnref68" class="footnote-back">↩</a></li>
<li id="fn69">Frances M Diro (<a href="2006-10-11" class="uri" title="wikilink">2006-10-11</a>). <a href="http://www.emedicine.com/neuro/topic673.htm">Urological Management in Neurological Disease</a>. <em><a href="eMedicine" class="uri" title="wikilink">eMedicine</a></em>. <a href="WebMD" class="uri" title="wikilink">WebMD</a>. Retrieved on <a href="2007-09-02" class="uri" title="wikilink">2007-09-02</a>.<a href="#fnref69" class="footnote-back">↩</a></li>
<li id="fn70"></li>
<li id="fn71"><a href="#fnref71" class="footnote-back">↩</a></li>
<li id="fn72"><a href="#fnref72" class="footnote-back">↩</a></li>
<li id="fn73"><a href="#fnref73" class="footnote-back">↩</a></li>
<li id="fn74"><a href="http://www.mayoclinic.com/print/ssris/MH00066/METHOD=print">Selective serotonin reuptake inhibitors.</a> Mayo Clinic (<a href="2006-12-08" class="uri" title="wikilink">2006-12-08</a>). Retrieved on <a href="2007-09-02" class="uri" title="wikilink">2007-09-02</a>.<a href="#fnref74" class="footnote-back">↩</a></li>
<li id="fn75"><a href="#fnref75" class="footnote-back">↩</a></li>
<li id="fn76"><a href="#fnref76" class="footnote-back">↩</a></li>
<li id="fn77"><a href="#fnref77" class="footnote-back">↩</a></li>
<li id="fn78"><a href="http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a697032.html">Donepezil.</a> US National Library of Medicine (Medline) (<a href="2007-04-01" class="uri" title="wikilink">2007-04-01</a>). Retrieved on <a href="2007-09-02" class="uri" title="wikilink">2007-09-02</a>.<a href="#fnref78" class="footnote-back">↩</a></li>
<li id="fn79"><a href="#fnref79" class="footnote-back">↩</a></li>
<li id="fn80"><a href="#fnref80" class="footnote-back">↩</a></li>
<li id="fn81"><a href="#fnref81" class="footnote-back">↩</a></li>
<li id="fn82"><a href="#fnref82" class="footnote-back">↩</a></li>
<li id="fn83"><a href="#fnref83" class="footnote-back">↩</a></li>
<li id="fn84"><a href="#fnref84" class="footnote-back">↩</a></li>
<li id="fn85"></li>
<li id="fn86"></li>
<li id="fn87"><a href="#fnref87" class="footnote-back">↩</a></li>
<li id="fn88"><a href="#fnref88" class="footnote-back">↩</a></li>
<li id="fn89"><a href="#fnref89" class="footnote-back">↩</a></li>
<li id="fn90"></li>
<li id="fn91"><a href="#fnref91" class="footnote-back">↩</a></li>
<li id="fn92"><a href="http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682064.html">Amantadine.</a> US National Library of Medicine (Medline) (<a href="2003-04-01" class="uri" title="wikilink">2003-04-01</a>). Retrieved on <a href="2007-10-07" class="uri" title="wikilink">2007-10-07</a>.<a href="#fnref92" class="footnote-back">↩</a></li>
<li id="fn93"><a href="#fnref93" class="footnote-back">↩</a></li>
<li id="fn94"><a href="http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682313.html">Pemoline.</a> US National Library of Medicine (Medline) (<a href="2006-01-01" class="uri" title="wikilink">2006-01-01</a>). Retrieved on <a href="2007-10-07" class="uri" title="wikilink">2007-10-07</a>.<a href="#fnref94" class="footnote-back">↩</a></li>
<li id="fn95"><a href="#fnref95" class="footnote-back">↩</a></li>
<li id="fn96"><a href="#fnref96" class="footnote-back">↩</a></li>
<li id="fn97"><a href="#fnref97" class="footnote-back">↩</a></li>
<li id="fn98"><a href="http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682237.html">Carbamazepine.</a> US National Library of Medicine (Medline) (<a href="2007-05-01" class="uri" title="wikilink">2007-05-01</a>). Retrieved on <a href="2007-09-02" class="uri" title="wikilink">2007-09-02</a>.<a href="#fnref98" class="footnote-back">↩</a></li>
<li id="fn99"><a href="http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682022.html">Phenytoin</a>. US National Library of Medicine (Medline) (<a href="2003-04-01" class="uri" title="wikilink">2003-04-01</a>). Retrieved on <a href="2007-09-02" class="uri" title="wikilink">2007-09-02</a>.<a href="#fnref99" class="footnote-back">↩</a></li>
<li id="fn100"><a href="#fnref100" class="footnote-back">↩</a></li>
<li id="fn101"><a href="#fnref101" class="footnote-back">↩</a></li>
<li id="fn102"><a href="http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682279.html">Clonazepam.</a> US National Library of Medicine (Medline) (<a href="2003-04-01" class="uri" title="wikilink">2003-04-01</a>). Retrieved on <a href="2007-09-02" class="uri" title="wikilink">2007-09-02</a>.<a href="#fnref102" class="footnote-back">↩</a></li>
<li id="fn103"><a href="http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682388.html">Amitriptyline.</a> US National Library of Medicine (Medline) (<a href="2007-08-01" class="uri" title="wikilink">2007-08-01</a>). Retrieved on <a href="2007-09-02" class="uri" title="wikilink">2007-09-02</a>.<a href="#fnref103" class="footnote-back">↩</a></li>
<li id="fn104"><a href="#fnref104" class="footnote-back">↩</a></li>
<li id="fn105"><a href="#fnref105" class="footnote-back">↩</a></li>
<li id="fn106"><a href="#fnref106" class="footnote-back">↩</a></li>
<li id="fn107"><a href="#fnref107" class="footnote-back">↩</a></li>
<li id="fn108"></li>
<li id="fn109"><a href="#fnref109" class="footnote-back">↩</a></li>
<li id="fn110"><a href="http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682530.html">Baclofen oral.</a> US National Library of Medicine (Medline) (<a href="2003-04-01" class="uri" title="wikilink">2003-04-01</a>). Retrieved on <a href="2007-10-17" class="uri" title="wikilink">2007-10-17</a>.<a href="#fnref110" class="footnote-back">↩</a></li>
<li id="fn111"><a href="http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682576.html">Dantrolene oral.</a> US National Library of Medicine (Medline) (<a href="2003-04-01" class="uri" title="wikilink">2003-04-01</a>). Retrieved on <a href="2007-10-17" class="uri" title="wikilink">2007-10-17</a>.<a href="#fnref111" class="footnote-back">↩</a></li>
<li id="fn112"><a href="http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682047.html">Diazepam.</a> US National Library of Medicine (Medline) (<a href="2005-07-01" class="uri" title="wikilink">2005-07-01</a>). Retrieved on <a href="2007-10-17" class="uri" title="wikilink">2007-10-17</a>.<a href="#fnref112" class="footnote-back">↩</a></li>
<li id="fn113"><a href="http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a601121.html">Tizanidine.</a> US National Library of Medicine (Medline) (<a href="2005-07-01" class="uri" title="wikilink">2005-07-01</a>). Retrieved on <a href="2007-10-17" class="uri" title="wikilink">2007-10-17</a>.<a href="#fnref113" class="footnote-back">↩</a></li>
<li id="fn114"><a href="#fnref114" class="footnote-back">↩</a></li>
<li id="fn115"><a href="#fnref115" class="footnote-back">↩</a></li>
<li id="fn116"><a href="#fnref116" class="footnote-back">↩</a></li>
<li id="fn117"></li>
<li id="fn118"><a href="#fnref118" class="footnote-back">↩</a></li>
<li id="fn119"><a href="#fnref119" class="footnote-back">↩</a></li>
<li id="fn120"><a href="#fnref120" class="footnote-back">↩</a></li>
<li id="fn121"><a href="#fnref121" class="footnote-back">↩</a></li>
<li id="fn122"></li>
<li id="fn123"><a href="http://www.mxga-mstrial.co.uk">United Kingdom early Mitoxantrone Copaxone trial.</a> Onyx Healthcare (<a href="2006-01-01" class="uri" title="wikilink">2006-01-01</a>). Retrieved on <a href="2007-09-02" class="uri" title="wikilink">2007-09-02</a>.<a href="#fnref123" class="footnote-back">↩</a></li>
<li id="fn124"><a href="http://www.genzyme.com/corp/media/GENZ%20PR-050207.asp">Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN.</a> Genzyme (<a href="2007-02-01" class="uri" title="wikilink">2007-02-01</a>). Retrieved on <a href="2007-09-02" class="uri" title="wikilink">2007-09-02</a>.<a href="#fnref124" class="footnote-back">↩</a></li>
<li id="fn125"><a href="http://www.pdl.com/index.cfm?navId=49">Daclizumab.</a> PDL Biopharma (<a href="2006-01-01" class="uri" title="wikilink">2006-01-01</a>). Retrieved on <a href="2007-09-02" class="uri" title="wikilink">2007-09-02</a>.<a href="#fnref125" class="footnote-back">↩</a></li>
<li id="fn126"><a href="http://www.clinicaltrials.gov/ct/show/NCT00067327">Treatment of Multiple Sclerosis Using Over the Counter Inosine.</a> ClinicalTrials.gov (<a href="2006-03-16" class="uri" title="wikilink">2006-03-16</a>). Retrieved on <a href="2007-09-02" class="uri" title="wikilink">2007-09-02</a>.<a href="#fnref126" class="footnote-back">↩</a></li>
<li id="fn127"><a href="http://www.clinicaltrials.gov/ct2/show/NCT00420212?term=biogen&amp;recr=Open&amp;rank=12">Efficacy and Safety of BG00012 in Relapsing-Remitting Multiple Sclerosis.</a> ClinicalTrials.gov (<a href="2007-09-1" class="uri" title="wikilink">2007-09-1</a>). Retrieved on <a href="2007-11-12" class="uri" title="wikilink">2007-11-12</a>.<a href="#fnref127" class="footnote-back">↩</a></li>
<li id="fn128"><a href="http://www.clinicaltrials.gov/ct/show/NCT00289978">Efficacy and Safety of Fingolimod in Patients With Relapsing-Remitting Multiple Sclerosis.</a> ClinicalTrials.gov (<a href="2006-02-09" class="uri" title="wikilink">2006-02-09</a>). Retrieved on <a href="2007-09-02" class="uri" title="wikilink">2007-09-02</a>.<a href="#fnref128" class="footnote-back">↩</a></li>
<li id="fn129"><a href="#fnref129" class="footnote-back">↩</a></li>
<li id="fn130"><a href="#fnref130" class="footnote-back">↩</a></li>
<li id="fn131"><a href="#fnref131" class="footnote-back">↩</a></li>
<li id="fn132"><a href="#fnref132" class="footnote-back">↩</a></li>
<li id="fn133"><a href="#fnref133" class="footnote-back">↩</a></li>
<li id="fn134"><a href="#fnref134" class="footnote-back">↩</a></li>
<li id="fn135"><a href="#fnref135" class="footnote-back">↩</a></li>
<li id="fn136"><a href="#fnref136" class="footnote-back">↩</a></li>
<li id="fn137"><a href="#fnref137" class="footnote-back">↩</a></li>
<li id="fn138"><a href="#fnref138" class="footnote-back">↩</a></li>
<li id="fn139">&gt;<a href="http://www.direct-ms.org/plannedresearch.html">Direct-MS Society - Clinical trials proposal and description</a> Direct-MS. Retrieved on <a href="2007-11-08" class="uri" title="wikilink">2007-11-08</a>.<a href="#fnref139" class="footnote-back">↩</a></li>
<li id="fn140"><a href="#fnref140" class="footnote-back">↩</a></li>
<li id="fn141"><a href="#fnref141" class="footnote-back">↩</a></li>
<li id="fn142"><a href="#fnref142" class="footnote-back">↩</a></li>
<li id="fn143"><a href="#fnref143" class="footnote-back">↩</a></li>
<li id="fn144"><a href="#fnref144" class="footnote-back">↩</a></li>
</ol>
</section>
